Parkinsonian signs and substantia nigra neuron density in decendents elders without PD

Substantia nigra (SN) neurons were counted on single, transverse caudal midbrain sections from 217 male participants in the Honolulu‐Asia Aging Study, aged 74–97 years at death. Quadrants areas within the SN were determined with a planimeter and neuronal density was expressed as neurons/mm2 for 10 Parkinson's disease (PD) cases, 29 incidental Lewy body cases, and 178 controls with neither condition. Mean densities in all quadrants were significantly lower in the PD group compared with the other groups (p = 0.006). This relationship was strongest in the ventrolateral quadrant. In a subgroup of 50 controls who were examined with the Unified Parkinson's Disease Rating Scale an average of 2.1 years prior to death, there was an association of stooped posture (p = 0.009), postural instability (p = 0.013), body bradykinesia (p = 0.048), and gait disturbance (p = 0.05) with neuron density in the dorsolateral quadrant; and impaired speech (p = 0.014), abnormal facial expression (p = 0.022), and difficulty rising from a chair (p = 0.032) with neuron density in the dorsomedial quadrant. There was a significant association of increasing number of signs present with decreasing neuron density in both quadrants (p = 0.001 for trend). Low SN neuron density may be the basis for parkinsonian signs in the elderly without PD. Ann Neurol 2004

[1]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[2]  S. Syme,et al.  Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary and biochemical characteristics. , 1974, Journal of chronic diseases.

[3]  P. W. Lane,et al.  Analysis of covariance and standardization as instances of prediction. , 1982, Biometrics.

[4]  Daniel L. McGee,et al.  Ten-year incidence of coronary heart disease in the Honolulu Heart Program. Relationship to biologic and lifestyle characteristics. , 1984, American journal of epidemiology.

[5]  L. Heilbrun,et al.  The origins of epidemiologic studies of heart disease, cancer and osteoporosis among Hawaii Japanese. , 1985, Hawaii medical journal.

[6]  P. Lewitt,et al.  Motor function in the normal aging population: treatment with levodopa. , 1985, Neurology.

[7]  Diane C. Tsai Recent Developments in Parkinson's Disease , 1986, The Yale Journal of Biology and Medicine.

[8]  S. Fahn Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[9]  C. Ward,et al.  Research diagnostic criteria for Parkinson's disease. , 1990, Advances in neurology.

[10]  Ward Cd,et al.  Research diagnostic criteria for Parkinson's disease. , 1990 .

[11]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[12]  S. Kish,et al.  Aging Produces a Specific Pattern of Striatal Dopamine Loss: Implications for the Etiology of Idiopathic Parkinson's Disease , 1992, Journal of neurochemistry.

[13]  J. H. Schuenemeyer,et al.  Generalized Linear Models (2nd ed.) , 1992 .

[14]  J. Langston,et al.  Aging and the nigrostriatal dopamine system: a non-human primate study. , 1994, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[15]  E. Teng,et al.  The Cognitive Abilities Screening Instrument (CASI): A Practical Test for Cross-Cultural Epidemiological Studies of Dementia , 1994, International Psychogeriatrics.

[16]  Eileen O. Smith,et al.  Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.

[17]  D. Charney,et al.  Age-Related Decline in Striatal Dopamine Transporter Binding with Iodine-123-β-CITSPECT , 1995 .

[18]  J. Rinne,et al.  Cell counts in the substantia nigra: a comparison of single section counts and disector counts in patients with Parkinson's disease and in controls , 1995, Neuropathology and applied neurobiology.

[19]  D. Morens,et al.  Epidemiologic observations on Parkinson's disease , 1996, Neurology.

[20]  L A Beckett,et al.  Prevalence of parkinsonian signs and associated mortality in a community population of older people. , 1996, The New England journal of medicine.

[21]  D J Foley,et al.  Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study. , 1996, JAMA.

[22]  J. Rinne,et al.  Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts , 1997, Journal of the Neurological Sciences.

[23]  Y. Stern,et al.  Pathological correlates of extrapyramidal signs in Alzheimer's disease , 1997, Annals of neurology.

[24]  D. Davis,et al.  Microscope field size and the neuropathologic criteria for Alzheimer's disease , 1997, Neurology.

[25]  J. Holden,et al.  Age‐related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys , 1998, The Journal of comparative neurology.

[26]  B T Hyman,et al.  Stereology: A Practical Primer for Neuropathology , 1998, Journal of neuropathology and experimental neurology.

[27]  R. Prettyman Extrapyramidal signs in cognitively intact elderly people. , 1998, Age and ageing.

[28]  A. Graybiel,et al.  The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. , 1999, Brain : a journal of neurology.

[29]  K. Jellinger Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms? , 1999, Journal of neural transmission. Supplementum.

[30]  A. Graybiel,et al.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.

[31]  C. Tanner,et al.  Association of coffee and caffeine intake with the risk of Parkinson disease. , 2000, JAMA.

[32]  A. Bonnet [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[33]  G. Gerhardt,et al.  Dopaminergic therapy improves upper limb motor performance in aged rhesus monkeys , 2000, Annals of neurology.

[34]  E. Wolters,et al.  Imaging of dopamine transporters with [123I]FP‐CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease , 2001, Synapse.

[35]  Eric R. Ziegel,et al.  Generalized Linear Models , 2002, Technometrics.

[36]  J. Seibyl,et al.  Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[37]  J. Touchon,et al.  Mild extrapyramidal signs and functional impairment in ageing , 2002, International journal of geriatric psychiatry.

[38]  Chris Zarow,et al.  Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis , 2003, Neurobiology of Aging.

[39]  Chris Zarow,et al.  Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. , 2003, Archives of neurology.